Structure of CARDS toxin, a unique ADP-ribosylating and vacuolating Cytotoxin from Mycoplasma Pneumoniae by Becker, Argentina et al.
Old Dominion University
ODU Digital Commons
Bioelectrics Publications Frank Reidy Research Center for Bioelectrics
4-2015
Structure of CARDS toxin, a unique ADP-






Old Dominion University, opakhomo@odu.edu
Yanfeng Zhang
See next page for additional authors
Follow this and additional works at: https://digitalcommons.odu.edu/bioelectrics_pubs
Part of the Biomedical Engineering and Bioengineering Commons
This Article is brought to you for free and open access by the Frank Reidy Research Center for Bioelectrics at ODU Digital Commons. It has been
accepted for inclusion in Bioelectrics Publications by an authorized administrator of ODU Digital Commons. For more information, please contact
digitalcommons@odu.edu.
Repository Citation
Becker, Argentina; Kannan, T. R.; Taylor, Alexander B.; Pakhomova, Olga N.; Zhang, Yanfeng; Somarajan, Sudha R.; Galaleldeen,
Ahmad; Holloway, Stephen P.; Baseman, Joel B.; and Hart, P. John, "Structure of CARDS toxin, a unique ADP-ribosylating and
vacuolating Cytotoxin from Mycoplasma Pneumoniae" (2015). Bioelectrics Publications. 27.
https://digitalcommons.odu.edu/bioelectrics_pubs/27
Original Publication Citation
Becker, A., Kannan, T.R., Taylor, A.B., Pakhomova, O.N., Zhang, Y., Somarajan, S.R., . . . Hart, P.J. (2015). Structure of CARDS toxin,
a unique ADP-ribosylating and vacuolating cytotoxin from Mycoplasma pneumoniae. Proceedings of the National Academy of Sciences,
112(16), 5165-5170. doi: 10.1073/pnas.1420308112
Authors
Argentina Becker, T. R. Kannan, Alexander B. Taylor, Olga N. Pakhomova, Yanfeng Zhang, Sudha R.
Somarajan, Ahmad Galaleldeen, Stephen P. Holloway, Joel B. Baseman, and P. John Hart
This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/bioelectrics_pubs/27
Structure of CARDS toxin, a unique ADP-ribosylating
and vacuolating cytotoxin from
Mycoplasma pneumoniae
Argentina Beckera,1, T. R. Kannanb,1, Alexander B. Taylora,c,1, Olga N. Pakhomovaa,d,1, Yanfeng Zhanga,
Sudha R. Somarajanb, Ahmad Galaleldeena,e, Stephen P. Hollowaya, Joel B. Basemanb,2, and P. John Harta,c,f,2
aDepartment of Biochemistry, bDepartment of Microbiology and Immunology/Center for Airway Inflammation Research, and cX-Ray Crystallography Core
Laboratory, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229; dFrank Reidy Center for Bioelectrics, Old Dominion University,
Norfolk, VA 23508; eDepartment of Biological Sciences, St. Mary’s University, San Antonio, TX 78228; and fSouth Texas Veterans Health Care System,
US Department of Veterans Affairs, San Antonio, TX 78229
Edited by R. John Collier, Harvard Medical School, Boston, MA, and approved March 10, 2015 (received for review October 22, 2014)
Mycoplasma pneumoniae (Mp) infections cause tracheobronchitis
and “walking” pneumonia, and are linked to asthma and other
reactive airway diseases. As part of the infectious process, the
bacterium expresses a 591-aa virulence factor with both mono-
ADP ribosyltransferase (mART) and vacuolating activities known
as Community-Acquired Respiratory Distress Syndrome Toxin
(CARDS TX). CARDS TX binds to human surfactant protein A and
annexin A2 on airway epithelial cells and is internalized, leading to
a range of pathogenetic events. Here we present the structure of
CARDS TX, a triangular molecule in which N-terminal mART and
C-terminal tandem β-trefoil domains associate to form an overall
architecture distinct from other well-recognized ADP-ribosylating
bacterial toxins. We demonstrate that CARDS TX binds phosphati-
dylcholine and sphingomyelin specifically over other membrane
lipids, and that cell surface binding and internalization activities
are housed within the C-terminal β-trefoil domain. The results en-
hance our understanding ofMp pathogenicity and suggest a novel
avenue for the development of therapies to treat Mp-associated
asthma and other acute and chronic airway diseases.
mycoplasma cytotoxin | single-crystal X-ray diffraction |
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The Centers for Disease Control and Prevention estimate that2 million people are infected with Mycoplasma pneumoniae
(Mp) each year, with 100,000 requiring hospitalization (1). The
bacterium is best known as a cause of atypical, or “walking,”
pneumonia (2, 3) and is increasingly appreciated for its role in
the etiology of reactive airway diseases, such as asthma and adult
respiratory distress syndrome (ARDS) (4, 5). Mp infection in-
duces cellular vacuolation and deterioration of ciliary movement,
eventually leading to cell death in the airway environment, as
well as a spectrum of extrapulmonary complications (6–9). Di-
agnosis of infection can be complicated by a latency period of up
to 3 wk, difficulties in cultivating the microorganism from clinical
specimens, inadequate diagnostic tools, and a broad spectrum of
clinical manifestations, some of which are similar to those of other
pulmonary conditions (2, 3). These characteristics, together with
the ability ofMp to evade the immune system through intracellular
localization and by adjusting its membrane composition to mimic
that of its host (6), have hindered a comprehensive understanding
of Mp infectious processes.
Mp was first detected in patients with atypical pneumonia, but
was believed to be a virus because it was resistant to penicillin
and sulfonamides and passed through bacteria-retaining filters
(10). Mycoplasmas are the smallest self-replicating life forms
identified and are postulated to have undergone genome re-
duction (11). Their streamlined genome size imposes nutritional
requirements that dictate a parasitic lifestyle. In this context,
during 50 y of study, the organism was believed to be devoid of
cytotoxins, a paradigm that shifted in 2005 when a 591-aa Mp
protein with mono-ADP ribosyltransferase (mART) and vacuo-
lating activities, termed Community-Acquired Respiratory Dis-
tress Syndrome Toxin (CARDS TX), was isolated through its
ability to bind with high affinity to surfactant protein A (SP-A), the
most abundant protein component of pulmonary surfactant (12–
14). The discovery of a previously unknown Mp virulence factor
cast Mp in a different light and opened the door for a new avenue
of research on what has historically been an enigmatic organism.
In the decade since the discovery of CARDS TX, advances
have been made in understanding the toxin’s role in Mp patho-
genicity and reactive airway disease. The gene encoding the toxin
and its promoter have been analyzed, and mRNA and protein
levels have been measured under various growth conditions (15).
Relative to SP-4 broth-grown Mp cultures, during infection of
mammalian cells, CARDS TX mRNA levels increase sub-
stantially. Analysis of infected mouse lung tissue revealed high
expression of CARDS TX compared with levels when grown in
SP-4 medium on a per cell basis. These data indicate CARDS
TX expression is up-regulated during Mp infection, possibly
owing to as-yet unidentified environmental cues (15).
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When removed from the context of the bacterium, recombi-
nant CARDS TX elicits the characteristic inflammation and
vacuolated airway histopathology in intoxicated mice in a dose-
dependent fashion, as observed with Mp organisms (16). Baboon
tracheal organ cultures exposed to purified toxin demonstrate
dose-dependent slowing and eventual cessation of cilia move-
ment and disruption of respiratory cell integrity (12). Naive mice
administered one dose respond with 30- to 80-fold increases in
the expression of Th-2 cytokines and chemokines, a robust eo-
sinophilia, accumulation of T and B cells, mucus metaplasia, and
airway hyperreactivity, suggesting that an analogous allergic-type
response in humans may play a causal role inMp-associated asthma
(16, 17). These studies reveal that CARDS TX recapitulates the
spectrum of respiratory pathologies associated with Mp infection.
The aforementioned results are consistent with CARDS TX
interaction with SP-A, which is abundant in mouse lung and
baboon tracheal rings; however, recombinant CARDS TX car-
ries out ADP-ribosylating and vacuolating activities in mamma-
lian cell lines that lack SP-A, suggesting that it uses alternative
receptors (18, 19). Using recombinant CARDS TX as bait, AnxA2
was isolated from the membrane fraction of A549 airway cells
(19). HepG2 cells express low levels of AnxA2, but on transfection
with a plasmid expressing AnxA2, toxin binding and cellular vac-
uolation are enhanced. NCI-H441 cells express both SP-A and
AnxA2, but on transfection with siRNAs specific for those proteins,
expression in these cells decreases relative to that in nontransfected
controls, and CARDS TX binding and cellular vacuolation are
proportional to AnxA2 and SP-A levels, although SP-A is preferred
as a binding target (19).
The acidic vacuoles induced by CARDS TX originate from
Rab9-associated compartments and are derived from the endo-
cytic pathway (18). The V-ATPase inhibitor bafilomycin A1 and
the ionophore monesin inhibit vacuole formation. The late en-
dosomal GTPase Rab9 is enriched at the vacuole membranes, an
observation confirmed by overexpression of GFP-Rab9 and the
use of immunogold-labeled Rab9. The late endosomal/lysosomal-
associated membrane proteins LAMP1 and LAMP2 are also lo-
calized to the vacuolar membranes, but the late endosomal pro-
tein Rab7 and early endosomal markers Rab5 and EEA1 are not.
HeLa cells expressing dominant-negative Rab9 demonstrate re-
duced vacuole formation, whereas those expressing dominant-
negative Rab7 do not. These data suggest that Rab9 is involved in
CARDS TX-mediated vacuole formation (18), although how
CARDS TX influences Rab9 association with vacuoles is unclear.
CARDS TX activates the NLRP3 inflammasome, an impor-
tant player in regulating the immune response during infection
via activation of procaspase-1, which in turn cleaves pro-IL-1β into
its mature form (20). The cytokine IL-1β dictates the severity of
inflammation associated with a spectrum of inflammatory dis-
eases. CARDS TX colocalizes with and activates the inflamma-
some via ADP ribosylation of NLRP3 (20), but CARDS TX
proteins with mutations that abrogate its mART activity and
truncated molecules that cannot be internalized by macrophages
do not. These results are relevant because inflammasome activa-
tion is known to contribute to lung remodeling and the devel-
opment of chronic airway diseases, such as asthma and chronic
obstructive pulmonary disease (21).
To better understand the molecular basis for the action of
CARDS TX, we crystallized (22) and determined its structure
using single-crystal X-ray diffraction. The architecture and do-
main organization of CARDS TX are unique relative to other
ADP-ribosylating bacterial toxins. Functional data demonstrate
that CARDS TX binds phosphatidylcholine (PC) and sphingo-
myelin (SM) specifically over other membrane lipids. Truncation
of the C-terminal 20 residues abrogates cell surface binding and
internalization, suggesting that receptor binding functions reside
in D3. The combination of structural and functional data pre-
sented herein serves as the starting point for the design of vac-
cine candidates and small molecules that block CARDS TX
action, providing an opportunity to reduce acute and chronic
Mp-related disease manifestations.
Results and Discussion
Overall Structure of CARDS TX. CARDS TX was crystallized as
described previously (22), and its structure was determined at
resolutions of 1.9 Å and 2.6 Å (Fig. 1, Fig. S1, and Table S1). The
toxin consists of 17 α-helices and 43 β-strands that fold into three
domains arranged in the shape of an isosceles triangle, with sides of
65 × 65 × 55 Å and a depth of 35 Å (Figs. 1 and 2). The N-terminal
mART domain (D1) associates with tandem C-terminal β-trefoil
subdomains (D2+D3) via a linker and an extensive interface. The
contacts between D1 and D2+D3 are predominantly polar (Fig. S1
C and D), suggesting that the interface can be disrupted.
CARDS TX mART Domain. A DALI search (23) of the Protein Data
Bank (PDB) returns the mART domains of pertussis toxin (PTx;
Bordetella pertussis; PDB ID code 1PRT) (24) and cholera toxin
(CTx; Vibrio cholerae; PDB ID code 2A5F) (25) as those most
similar to D1. The mART domains of all three toxins have the
R–STS/T–E signature motif characteristic of ADP-ribosylating
toxins of the cholera toxin subgroup (CTxg) (26) (Fig. 3A). When
structurally aligned, the active site signature residues are con-
served in 3D space despite limited overall sequence identity (Fig.
3B). The N-terminal arginine (R10) and the midregion Ser-Thr-Ser
(S49-T50-S51) are predicted to bind and orient NAD+, whereas
the invariant catalytic Glu (E132) is responsible for the trans-
ferase activity (12, 27). The six residues preceding and two
residues following E132 form the ADP-ribosylating turn-turn
(ARTT) motif (Fig. 3A and Fig. S2), which is believed to par-
ticipate in target protein recognition (28). The CARDS TX
ARTT motif is distinct from other bacterial mART domains
(Fig. 3A), and the immediately preceding residues 94–126 form
a helix-strand-helix motif (H4-S6-H5) that comprises the D1
component of the D1+D3 interface (Fig. 1 and Fig. S1 A and D).
Steric Blocks of CARDS TX mART Activity. The conformation of
CARDS TX shown in Fig. 1 does not appear competent to act on
target proteins, because the active site and target recognition
elements are inaccessible. Residues 206–256 form a physical
barrier similar to that of PTx (Fig. 4 A and B and Fig. S2) that
renders the NAD+-binding site inaccessible. Residues 127–134
containing the catalytic E132 residue and the target-protein
recognition ARTT motif are buried by this barrier and by the
extensive interface between D1 and D2+D3 (Fig. 4 C and D and








Fig. 1. CARDS TX tertiary structure. In all figures, the D1 mART domain is
shown in light blue, the steric block of the NAD+-binding pocket is violet, the
linker connecting D1 to D2+D3 is dark red, D2 is dark blue, D3 is green, Cys-Sγ
atoms are yellow spheres, and F591 is bright red. The aromatic patch in D3 is
shown as orange sticks.
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interact with E52 and R131 positioned adjacent to the S49-T50-
S51 and catalytic E132 residues of the signature sequence, re-
spectively (Fig. 4E and Fig. S2C).
CARDS TX β-Trefoil Domains. The tandem C-terminal domains
D2+D3 are similar in fold and relative orientation to those of
ricin B (PDB ID code 2AAI) (29). Unlike ricin B, however, the
CARDS TX D2+D3 β-trefoils do not have galactose-binding
sites, and the protein is negative for saccharide binding when
screened against mammalian glycans in chip-based array exper-
iments at the Consortium for Functional Glycomics. A striking
feature of CARDS TX D3 is its aromatic amino acid content (35
of 152 residues), 15 of which cluster to form an aromatic patch
reminiscent of that found in the cytolethal distending toxin
(CDT) from Haemophilus ducreyi (PDB ID code 1SR4) (30)
(Fig. 1 and Fig. S3). Mutagenesis of the aromatic patch in CDT
interferes with cell surface binding and internalization (31).
Similarly, and in contrast to the wild type protein, a CARDS TX
truncation variant lacking residues 571–591 is not internalized by
HeLa cells (Fig. S4A). Residues 571–591 are integral to the
proper folding of D3 and formation of its aromatic patch (Fig.
S4B). These data suggest that entry of CARDS TX into host cells
is mediated by D3. Previous work indicated that CARDS
TX-mediated vacuolating activity also resides in D2+D3 and is
independent of D1 or mART activity, because catalytic mutants
Arg10Ala, His36Ala, and Glu132Ala and N-terminal truncation
variants 178CARDS591 and 264CARDS591 all induce vacuolation
when incubated with HeLa cells as efficiently as the native toxin (27).
CARDS TX Binds PC and SM, But Not Other Membrane Lipids. Previous
data indicate that SP-A and AnxA2 serve as independent re-
ceptors for CARDS TX binding and vacuolation (12, 19); how-
ever, binding and vacuolation were also noted in the absence of
these proteins (19), prompting a search for nonproteinaceous
receptors. Although negative for glycan binding, CARDS TX
binds PC and dipalmitoylphosphatidylcholine (DPPC) specifi-
cally over choline, phosphatidic acid, and other membrane lipids
(Fig. 5A). Using a larger panel of membrane-associated lipids,
we found that full-length CARDS TX and D2+D3 alone bind PC
and SM, but D1 alone does not (Fig. 5B). PC and SM differ in their
backbones, but both have phosphocholine head groups. Phos-
phocholine-containing membrane lipids are enriched in the outer
leaflet of the plasma membrane, whereas phospholipid molecules
containing a terminal primary amino group (e.g., phosphatidyl-
ethanolamine, phosphatidylserine) are present predominantly in
the inner leaflet (32). Airway cells are covered by pulmonary
A
B C
Fig. 2. CARDS TX secondary structure. (A) Secondary structure observed crystallographically as a function of amino acid sequence. (B) The D1 mART domain
lacking the steric block labeled according to A. The view is ∼90° around the horizontal relative to Fig. 1. (C) Divergent stereo pair in the same orientation as
Fig. 1 showing the steric block of the NAD+-binding pocket, linker, and D2+D3 β-trefoil domain structural elements labeled as in A.









surfactant, which is ∼40% DPPC, ∼40% PC, ∼5% surfactant
proteins (i.e., SP-A, -B, -C, and -D), cholesterol, and other sub-
stances (14, 33). When adsorbing to the air–water interface of
alveoli, the hydrophilic head groups are oriented in the water and
the hydrophobic tails face the airspace, enabling PC and DPPC to
reduce surface tension, thereby facilitating lung expansion (34).
SP-A is known to associate directly with DPPC (35). Although
some bacterial toxins, such as botulinum neurotoxin type A (36),
use protein and membrane lipid components as coreceptors,
whether PC and SM serve as coreceptors for CARDS TX re-
mains to be determined.
Unique Architecture of CARDS TX. The combination of catalytic and
cell surface binding activities and the composition and spatial
arrangement of CARDS TX domains is unique among the family
of bacterial ADP-ribosylating toxins (reviewed in ref. 37). The
mART domains of PTx (24) (Figs. 3B and 4B), CTx (38) (Fig.
3B), and heat-labile enterotoxin (39) are the most closely related
to CARDS TX D1 (Fig. 2A), but in lieu of β-trefoils, they have
pentameric assemblies of polypeptides that bind carbohydrates
(Fig. S5 A and B). To our knowledge, mosquitocidal toxin is the
only other bacterial toxin with solely mART and β-trefoil do-
mains (40), but its organization differs, with four (nontandem)
β-trefoil domains connected by flexible linkers to form “beads on
a string” that encircle the catalytic mART domain (Fig. S5D).
Although CARDS TX, CDT, and ricin might be considered
generally similar in architecture in that each has a cytotoxic
catalytic domain paired with two β-trefoil domains, CARDS TX
remains unique relative to these toxins from a functional per-
spective, because ricin and CDT have N-glycoside hydrolase (41)
and nuclease (30) catalytic activities, respectively.
Summary of CARDS TX Structure/Function Relationships. The struc-
tural and functional data presented here provide insight into this
latest addition to the group of ADP-ribosylating bacterial toxins.
CARDS TX activates the NLRP3 inflammasome via ADP
ribosylation of its NLRP3 component (20). The molecular basis
for CARDS TX–inflammasome interactions likely involves the
CARDS TX ARTT and the adjacent H4-S6-H5 motifs (Fig. 3 A























































Fig. 3. CARDS TX is a member of the CTx subgroup (CTxg) of bacterial mART domains. (A) Structure-based alignment of ADP-ribosylating toxins from the
cholera (CTxg) and diphtheria toxin (DTxg) subgroups. CARDS TX secondary structure is indicated at the top. The R–STS/T–E signature motif is shared by CTxg
members (yellow). ARTT residues are in cyan. The S6-H5 portion of the H4-S6-H5 motif found only in CARDS TX is boxed. (B) CARDS TX (light blue) and PTx





















Fig. 4. Steric blocks of CARDS TX and PTx mART active sites. The R–STS/T–E signature motif residues are colored as in Fig. 3A. (A) CARDS TX mART domain.
C230 and C247 within the steric block form a disulfide bond (yellow spheres). The view is as in Fig. 2B. (B) PTx mART domain. C41 and C201 form a disulfide
bond (yellow spheres) linking the steric block to the N-terminal portion of the mART domain. (C) Surface representation highlighting the steric block of the
CARDS TX NAD+-binding pocket. (D) Catalytic and substrate recognition residues are buried at the D1/D2D3 interface. D2 and D3 have been removed for clarity.
A tunnel into the active site runs adjacent to the ARTT motif. The yellow surface inside the tunnel is E132. (E) 1.9-Å electron density with coefficients 2mFo − DFc
contoured at 1.2 σ superimposed on the refined CARDS TX structure. The C-terminal residues of the toxin, R590 and F591, project into the active site.
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interface (Fig. 1 and Fig. S1D). The available data do not reveal
the specific CARDS TX residues that interact with cell surface
lipids and protein receptors, but they do indicate that PC, DPPC,
and SM binding activities are housed within D2+D3 (Fig. 5B).
CARDS TX D2+D3 domains were previously reported to me-
diate binding, internalization, and vacuolation activities (19, 27).
The crystal structure suggests that deletion of residues 571–591
in D3 or residues 274–308 in D2 will severely disrupt the integrity
of the β-trefoil domains in which they reside (Fig. S4 B and C).
Importantly, the former truncation abrogates binding and in-
ternalization (Fig. S4A) but the latter truncation does not (27),
implicating D3 as the mediator of these activities.
The steric blocks of target recognition elements and the NAD+-
binding sites suggest that CARDS TX-mediated ADP ribosyla-
tion requires a conformational change or proteolytic nicking to
permit the separation of D1 from D2+D3. This notion seems
plausible, given previous work demonstrating that D1 and D2+D3
in isolation retain their respective mART and binding and
internalization activities (27). The solvent-exposed loop between
Cys230 and Cys247 is a candidate for a proteolytic cleavage event,
because residues 237–241 of this loop are disordered in all seven
CARDS TX molecules in the present study (Fig. 1 and Fig. S1 A
and B), and flexible loops are often targets of protease action. A
cleavage event in this loop followed by reduction of the C230–
C247 disulfide bond is predicted to relieve the autoinhibitory
block of the NAD+-binding site in D1 and may cause dissociation
of the N- and C-terminal portions; however, reduction of the
Cys230–Cys247 disulfide bond itself may relieve the steric blocks
of the NAD+-binding pocket, active site, and ARTT target rec-
ognition motif while leaving D2+D3 tethered to D1.
Because Mp is implicated in many airway and extrapulmonary dis-
eases, and because CARDS TX alone replicates the cell injury asso-
ciated withMp infection, the structure serves as a starting point for the
design of vaccine candidates and small molecules that block CARDS
TX action, thereby affording the opportunity to eliminate/reduce a
wide range of acute and chronic Mp-related disease manifestations.
Materials and Methods
Protein Expression and Purification. “Nicked” CARDS TX was generated, puri-
fied, and crystallized as described previously (22). “Unnicked” CARDS TX was
expressed and purified using the same protocol except that (i) cells were grown
in Terrific Broth; (ii) the N-terminal 8× His tag was not removed; (iii) the protein
was dialyzed against buffer containing 25 mM Hepes, pH 7.5, and 2 mM TCEP;
and (iv) the protein was concentrated to ∼10 mg/mL for crystallization trials.
Crystallization and Data Collection. Nicked CARDS TX crystallized in space
group C2 as described previously (22). Unnicked CARDS TX crystallized in
space group R3 using the sitting-drop vapor diffusion method and a Phoenix
liquid-handling robot (Art Robbins Instruments). The reservoir solution
(Qiagen PEG II suite) contained 30% PEG 1000 and 0.1 M Tris·HCl pH 8.5. The
PEG 1000 present in the mother liquor was a suitable cryoprotectant, and
the crystals were mounted directly onto nylon cryoloops and flash-frozen.
Diffraction data from unnicked CARDS TX crystals were obtained at the
Advanced Photon Source of the Argonne National Laboratory on beamline
24-ID-E using an ADSC Q315 detector (315 mm × 315 mm). Diffraction data
were processed using the HKL-2000 program package (42).
Structure Determination and Refinement. Crystals of nicked CARDS TX contain
six molecules in the asymmetric unit, and crystals of unnicked CARDS TX
contain one molecule in the asymmetric unit. The nicked CARDS TX structure
was determined using single isomorphous replacement with anomalous
scattering (SIRAS) by pressurizing a xenon chamber (Hampton Research) to
400 psi for 15 min before flash-cooling. Xenon positions were determined
using SHELXD (43). Phases from 27 xenon sites were calculated and refined in
SHARP (44), followed by density modification in RESOLVE (45). Sixfold
noncrystallographic symmetry (NCS) averaging produced an electron density
map of quality sufficient to obtain a Cα backbone trace. Phases calculated
from the Cα backbone combined with the experimental phases yielded a
phase set suitable for automated structure building in PHENIX (46). The six
CARDS TX molecules in the asymmetric unit were refined without NCS re-
straints in PHENIX alternating with manual rebuilding in COOT (47).
The structure of unnicked CARDS TX was determined by molecular re-
placement in PHENIX using the nicked CARDS TX protomer A as the search
model, followed by iterative rounds of refinement and model adjustment.
Structure validation was performed by PROCHECK (48). The coordinates and
structure factors are available in the PDB (ID codes 4TLV and 4TLW). All
structural figures were created using PyMol version 1.7 (Schrödinger).
ELISA Lipid-Binding Analyses.Microtiter plate (Immunoplate; Nunc) wells were
coatedwith 50 μL of phospholipids found in cell membranes (125–500 ng/well).
After drying, wells were washed twice with PBS and blocked with 200 μL of
1 mg/mL BSA in PBS for 1 h at 37 °C. Then CARDS TX (100 ng/well) was added,
followed by incubation for another 1 h at 37 °C. After thorough washing with
PBS, anti-CARDS TX polyclonal antibody (1:4,000 dilution in 1% skim milk/PBS)
was added. The wells were again washed with PBS, and HRP-conjugated goat
anti-rabbit secondary antibody (Invitrogen; 1:2,000 dilution in 1% skimmilk/PBS)
was added, followed by a 45-min incubation and then the addition of 3,3′,5,
5′-tetramethylbenzidine substrate and measurement at 450 nm. Wells coated
with BSA alone served as negative controls.
Dot Blot Lipid-Binding Analyses. Toxin binding to membrane lipids was ana-
lyzed using membrane-associated lipids (Membrane Lipid Strips), phosphoi-
nositides (PIP Strips), and sphingolipids (SphingoStrips) in accordance with the
instructions from the manufacturer (Echelon Biosciences). Membranes were
blocked for 2 h in 4% (wt/vol) skim milk or BSA dissolved in PBS. Then purified
CARDS TX at 10 μg/mL was added, and membranes were incubated overnight
at room temperature on a rotary shaker. Membranes were washed three times
in PBS and incubated with anti-CARDS TX polyclonal antibody (1:4,000 dilution
in 1% skim milk/PBS), followed by alkaline phosphatase-conjugated goat anti-
rabbit secondary antibody (1:2,000 dilution in 1% skim milk/PBS).
CARDS TX Cell Surface Binding and Internalization. The binding and inter-
nalization of the full-length and truncated 1–570 CARDS TX variant were
analyzed as described previously (49).
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Fig. 5. CARDS TX binds PC, DPPC, and SM specifically
over other membrane lipids. (A) ELISA and (B) dot blot
analyses of CARDS TX binding to a panel of diverse
membrane lipids and their components as described in
Methods. Full-length, D1, and D2+D3 constructs were
tested. The 16 lipids/lipid components on each strip are
(1) triglyceride, (2) diacylglycerol, (3) phosphatidic acid,
(4) phosphatidylserine, (5) phosphatidylethanolamine,
(6) PC, (7) phosphatidylglycerol, (8) cardiolipin, (9) phos-
phatidylinositol, (10) phosphatidylinositol 4-phosphate,
(11) phosphatidylinositol 4,5-bisphosphate, (12) phos-
phatidylinositol 3,4,5-trisphosphate, (13) cholesterol, (14)
SM, (15) 3-sulfogalactosylceramide, and (16) blank.
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